| Popis: |
Blanka Wolszczak Biedrzycka,1,2 Anna Bieńkowska,1,2 Elwira Smolińska-Fijołek,3 Grzegorz Biedrzycki,4 Justyna Dorf5 1Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn, Olsztyn, 10-082, Poland; 2The Oncology Center of the Region of Warmia and Mazury in Olsztyn, Hospital of the Ministry of the Interior and Administration, Olsztyn, 10-228, Poland; 3Department of Physiology, Medical University in Gdańsk, Gdańsk, 80-211, Poland; 4Hospital Dispensary, Regional Specialist Hospital in Olsztyn, Olsztyn, 10-561, Poland; 5Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Bialystok, 15-269, PolandCorrespondence: Blanka Wolszczak Biedrzycka, Tel +48-505-970-699, Email blanka.wolszczak@gmail.comIntroduction: A global vaccination program was implemented in late 2020 to end the pandemic caused by the SARS-CoV-2 virus. However, the immune response elicited by the vaccines proved to be insufficient due to the rapid emergence of new viral mutations. Therefore, the factors influencing cellular and humoral immune responses after the administration of different vaccines against SARS-CoV2 need to be identified.Materials: In the present study, anti-SARS-CoV-2 antibody titers were analyzed 20 to 50 days after the administration of a third (booster) dose of the BNT162b2 vaccine in 192 residents of the city of Olsztyn (Poland) primed with two AstraZeneca or Pfizer/BioNTech vaccines.Methods: Antibody titers were determined in venous blood serum in the ECLIA test using the Cobas e411 Roche analyzer.Results: The study revealed that persons who received three doses of the Pfizer/BioNTech vaccine had significantly higher antibody titers than those who received two doses of AstraZeneca and a booster dose of Pfizer/BioNTech.Keywords: vaccination, COVID-19, BNT162b2, ChAdOx1, anti-SARS-CoV-2 |
